Congress is going to investigate!

[Anonymous]

it gets more interesting every day

http://www.pharmalot.com/2008/07/congress-to-probe-ranbaxy-allegations/

[Anonymous]

Rivals are at the root of this Congressional investigation too. Just like they were for the inspection we failed in Paonta. And Dewas. And Bata Mandi. Not to forget the gabapentin recall. And the stock plunge on Monday and Tuesday.

Nobody loves us. Boohoo.

[Anonymous]

The incompetence of Ranbaxy management from the US Regional Director and CEO is truly breathtaking. I guess that is what happens when a little boy who never accomplished anything on his own becomes CEO of an international company.

When these problems came to light 3 years ago all they had to do was appoint the right people to resolve them. All that it would have taken was to admit that Ranbaxy had problems and honestly work with the FDA to resolve them.

Instead their arrogance and stupidity has now brought these problems out where everyone will soon see them. Even though Ranbaxy's problems were serious they now will be greatly magnified in the public eye and people will end up beleiving they were even worse than they actually are.

How much longer will the buyers at Ranbaxy customers be able to justify to their bosses a decision to buy Ranbaxy products?

How much longer will Diiachi remain associated with this reputation killer?

Maybe one day management of Indian companies will have the vision to understand that you can't send Indians to run a company in the US and expect good results. They don't understand how to operate in a highly regulated market and seemingly don't have the integrity or judgment to give real decision making authority to people who do.

[Anonymous]

it gets more interesting every day

http://www.pharmalot.com/2008/07/congress-to-probe-ranbaxy-allegations/

Most of the U.S. managers seemed to think that the congressional investigation could be a good thing, and that the FDA would be forced to acknowledge that Ranbaxy's products are safe and in compliance with FDA guidelines. If we are innocent of these allegations, that is a pretty valid point and would probably help with customers.

I'd be interested to know if anyone else agrees with that theory. Serious responses only please.

[Anonymous]

Most of the U.S. managers seemed to think that the congressional investigation could be a good thing, and that the FDA would be forced to acknowledge that Ranbaxy's products are safe and in compliance with FDA guidelines. If we are innocent of these allegations, that is a pretty valid point and would probably help with customers.

I'd be interested to know if anyone else agrees with that theory. Serious responses only please.

Instead of believing outright the drivel dished out of Gurgaon, what most U.S. managers really need to be thinking is this:

What if the congressional investigation opens a whole new can of worms and the laundry that is aired in public turns out to be embarassingly soiled?

What if the internal consensus that the FDA has nothing on us and is only doing this to save face is misplaced? What if the confidence being exuded out of India turns out to be overconfidence?

And most importantly, what are Ranbaxy's chances of coming out on top in a battle with the FDA?

Positive thinking is good. Realistic thinking is better.

[Anonymous]

Ask yourself one simple question: If the FDA's actions have been without any basis why hasn't Ranbaxy sued the FDA to force approval of products from the two plants in India that are involved in the investigation?

Ranbaxy has not gotten any approvals out of its 2 plants in India for almost 3 years. Ranbaxy has never been reluctant to sue the FDA in other instances where management believes the FDA imporperly denied or delayed approvals.

Despite its public comments by its inaction Ranbaxy management has admitted that there is merit in the FDA's action. Anyone who thinks otherwise is uninformed or delusional.

[Anonymous]

The incompetence of Ranbaxy management from the US Regional Director and CEO is truly breathtaking. I guess that is what happens when a little boy who never accomplished anything on his own becomes CEO of an international company.

...

Maybe one day management of Indian companies will have the vision to understand that you can't send Indians to run a company in the US and expect good results.

The less said the better about a CEO who has not visited the US, Ranbaxy's single biggest market, for more than two years now. You tell me this - is it more important to be seen in Davos every year rubbing shoulders with the who's-who than to go meet your customers and employees in the country that gives you nearly a third of your total global sales? These things aren't going unnoticed by employees or customers.

And about sending Indians to run Indian companies - ain't gonna change anytime soon, mate. They will send people to run the show who have a stellar academic record but zero soft skills. The assumprion is that if they were good in school, they will be good in the real world as well. So what happens is that these highly qualified managers are either introverted and underconfident or unpolished and abrasive.

What is worse still is that sometimes they will send untested and unqualified distant relatives to handle key functions! The level of nepotism is utterly appalling.

[Anonymous]

Ask yourself one simple question: If the FDA's actions have been without any basis why hasn't Ranbaxy sued the FDA to force approval of products from the two plants in India that are involved in the investigation?


This is a great question and I hope someone asks it at the next open forum in two weeks. You can say what you want about US management, but few places I have ever worked will the president stand there and answer questions from lower level employees.

[Anonymous]

This is a great question and I hope someone asks it at the next open forum in two weeks. You can say what you want about US management, but few places I have ever worked will the president stand there and answer questions from lower level employees.

That would be worth complementing if you were being told the truth.

Have you not figured out that such meetings are all part of the manipulation??

[Anonymous]

The less said the better about a CEO who has not visited the US, Ranbaxy's single biggest market, for more than two years now. You tell me this - is it more important to be seen in Davos every year rubbing shoulders with the who's-who than to go meet your customers and employees in the country that gives you nearly a third of your total global sales? These things aren't going unnoticed by employees or customers.

And about sending Indians to run Indian companies - ain't gonna change anytime soon, mate. They will send people to run the show who have a stellar academic record but zero soft skills. The assumprion is that if they were good in school, they will be good in the real world as well. So what happens is that these highly qualified managers are either introverted and underconfident or unpolished and abrasive.

What is worse still is that sometimes they will send untested and unqualified distant relatives to handle key functions! The level of nepotism is utterly appalling.

The CEO hasn't visited because he is afraid he will be detained for questioning by the FDA crminal division or DOJ --that tells you something.

As you indicate good academics don't make a good manager. But, I have seen little evidence that the ones sent to the US have superior intellect; if they did well in school they must have attended some substandard schools.

[Anonymous]

This is a great question and I hope someone asks it at the next open forum in two weeks. You can say what you want about US management, but few places I have ever worked will the president stand there and answer questions from lower level employees.

The real answer to that questions is: "The FDA had been asking us for documents and reports related to the Paonta facility for two years. But we kept denying them access and stalling them by claiming confidentiality privileges of all kinds. It was therefore a little difficult for us to sue them for not giving us approvals!"

However, the answer that will be provided in the Open Forum will be a combination of: "Our outside lawyers advised us not to do this since it is risky to challenge the FDA so often as it can Ranbaxy's business interests in the long term. The decision was taken by management in India and we do not know the thinking behind it. We could not challenge the FDA because the investigation was underway and results had not been shared with us."

Do not be surprised if the Open Forum is postponed indefinitely.

[Anonymous]

However, the answer that will be provided in the Open Forum will be a combination of: "Our outside lawyers advised us not to do this since it is risky to challenge the FDA so often as it can Ranbaxy's business interests in the long term. The decision was taken by management in India and we do not know the thinking behind it. We could not challenge the FDA because the investigation was underway and results had not been shared with us."

Look what you've gone and done....now they will have to redevelop and reword their message points for the Open Forum to give this a different spin.

[Anonymous]

Rivals are at the root of this Congressional investigation too. Just like they were for the inspection we failed in Paonta. And Dewas. And Bata Mandi. Not to forget the gabapentin recall. And the stock plunge on Monday and Tuesday.

The company is now blaming a mysterious foreign pharma company for trying to derail the Daiichi deal. (Are they taking cues from our government which likes to blame everything on 'forces operating on foreign soil'?) The company is also investigating the purchase and sale of its shares earlier this week that led to the obliteration of a fourth of its market capitalization in 2 days.

That's a fair bit of sleuthing, right? Hmmm...makes you wonder if the company is now in the investigation business as well? Maybe the FDA should outsource its investigation of wrongdoings at Ranbaxy to....yes, you guessed it....Ranbaxy!!!!

[Anonymous]

The company is now blaming a mysterious foreign pharma company for trying to derail the Daiichi deal. (Are they taking cues from our government which likes to blame everything on 'forces operating on foreign soil'?) The company is also investigating the purchase and sale of its shares earlier this week that led to the obliteration of a fourth of its market capitalization in 2 days.

So let me get this straight. Ranbaxy says the FDA and DoJ charges are baseless yet goes on to make unproven allegations itself?!

Guys - either spit out the name(s) of the company/ies trying to to this or keep your trap shut. And try not to insult our intelligence by blaming everything on the big, bad but WHOLLY IMAGINARY wolf.

And will someone please wake up the media? They are trained and paid to have inquiring minds, yet they obediently parrot whatever the company says instead of taking pause to question how ridiculous some of the company's claims are.

[Anonymous]

The CEO hasn't visited because he is afraid he will be detained for questioning by the FDA crminal division or DOJ --that tells you something.

Wow. If that is the real reason, then it says it all, doesn't it? Maybe someone should raise this in the Open Forum as well....I hope employees and customers are taking note.

[Anonymous]

Wow. If that is the real reason, then it says it all, doesn't it? Maybe someone should raise this in the Open Forum as well....I hope employees and customers are taking note.

If you believe that, then I have a bridge to sell you. Even if these things that were alleged to have happened, did actually happen, Malvinder Singh is so far removed from the business he would have no idea.

[Anonymous]

If you believe that, then I have a bridge to sell you. Even if these things that were alleged to have happened, did actually happen, Malvinder Singh is so far removed from the business he would have no idea.

Malav, like his predecessor CEOs, have been well aware of and at least tacilitly supportive of the fraudulent activities that have been going on at least since RM was head of generic product development. If anyone thinks this is just a few low level "yahoos in India" as one writer described them he is a fool and has swallowed Ranbaxy's BS.

Malav and his legal counsel, the one who lead the Atorva litigation debacle(JD), have also made every significant decision, and many insignificant decisions, in handling the interaction with the FDA.

[Anonymous]

If you believe that, then I have a bridge to sell you. Even if these things that were alleged to have happened, did actually happen, Malvinder Singh is so far removed from the business he would have no idea.

I repeat - Malav is not visiting the US because he does not want to be detained by the FDA or DoJ for questioning and interrogation. It is on the advice of his lawyers and legal counsel, who by the way appear to have been deciding the course for the company the past few years, that he has stayed away. If he has nothing to hide or fear and is, as you say, far removed from the business to know anything, why is he sitting here holding press conferences and talking to media instead of being were the action is?

By staying away, he has demonstrated how weak he really is. If a crisis that threatens its biggest market had struck any other company, the company's CEO would be on the ground running the operation himself. Malav should be in the US demonstrating leadership...reassuring employees, talking to customers and meeting Congressmen and representatives from the FDA. Instead, he is sitting here surrounded by his posse of chamchas (psychophants) concentrating solely on making sure his dear deal does not go awry. The message that's coming through is "all I care about is my billions. To hell with this company that was built on the blood, sweat and tears of my forefathers. And to hell with the FDA, the DoJ and Congress too. This is no longer my headache. Hasta la vista, baby."

[Anonymous]

If you believe that, then I have a bridge to sell you. Even if these things that were alleged to have happened, did actually happen, Malvinder Singh is so far removed from the business he would have no idea.

Maybe its because he is so far removed from the business that he is moving himself even further through this deal? I think he realises that he has neither his father's business acumen and vision, nor his grandfather's guile and street smarts. Might as well cash in your chips when you're still ahead, no?

The buck stops at the CEO's door and you can't really cite ignorance as your defense in court, or a Congressional Committe hearing for that matter.

[Anonymous]

I think at this point it would be logical to assume a few things:

1. If the DOJ had any hard evidence of the really bad allegations, they would have brought charges already.
2. The above statement aside, Ranbaxy isn't getting out of this thing completely scott free, there will be some type of fine or concession, maybe closing Paonta.
3. The Daiichi buyout is probably the best thing to happen to Ranbaxy, as they will make sure, on a going forward basis, company will meet all FDA guidelines.
4. Malvinder's days are numbered. Daiichi isn't going to leave a child CEO in control of a multi-billion dollar company. It won't be immediate, but within 12 months Malvinder will "step down" to pursue other interests.

[Anonymous]

You have to feel sorry for the poor slobs at Diiachi who recomended to senior management and their board that they purchase a majority stake in Ranbaxy at any price much less a price 727 or whatever it is.

Does seppuku come to mind?

[Helward]

Talk about unfortunate timing. Barely a month after Ranbaxy Laboratories, India’s largest drug maker, entered into a landmark deal to sell out to Japan’s pharmaceutical major Daiichi Sankyo, it now has the U.S. Food and Drug Administration out for blood over Ranbaxy’s alleged concealment and forgery of crucial data to swing an FDA judgment in its favor. To make matters worse, there are also now allegations of selling substandard HIV drugs to AIDS patients in Africa.

Not surprisingly, the company’s shares tanked 10% on Monday, and fell another 14% on Tuesday.

In 2007, it took on Drug giant Pfizer in 17 countries, when it filed for the right to make generic versions of the world’s best selling cholesterol drug Lipitor and later a combination drug Caudet. Pfizer contested the move. In June 2008, the two companies finally settled the dispute, Pfizer allowing Ranbaxy to sell a generic version of Lipitor from Nov 2011.


Whatever the outcome of Ranbaxy’s current controversy, there is tremendous pressure on the company’s deal with Daiichi. Both the companies have pledged to carry the deal through. But my bet is Daiichi’s board must be putting the company’s execs through some pretty rough grilling at the moment. For my colleague Bruce Einhorn’s take on the deal when it was announced, click here.

The company has also struggled with its new drug discovery program and has abandoned plans of hiving off the business.

[Nandini]

There is more to it than meets the eye, is the refrain from domestic drug industry officials, watching with concern the constantly changing developments on Ranbaxy’s tryst with the United States regulatory authorities.

Even as questions are being raised on the documentation and quality of drugs that Ranbaxy sold in the US, latest media reports from the US say that the US Congress too is now examining the role of the regulatory US Food and Drug Administration (FDA), since the Ranbaxy issue has been on for the last three years.

(In a communication to the stock exchanges, Ranbaxy today said: “We are not aware of any Congressional committee inquiry and have not received any communication in this regard.” Its shares were down nearly 4 per cent on the NSE today at Rs 452.50.)

But for the Indian generic drugs industry, that has constantly had to ward off doubts cast on its quality and efficacy, the Ranbaxy stand-off in the US is disconcerting. The fear being that the generic industry will now more so be viewed with suspicion, never mind how Ranbaxy’s case pans out.

Allegations
Ranbaxy had been put under the scanner, for what the US Department of Justice (DoJ) describes as “systemic fraudulent conduct” including submissions made by the company to the FDA on stability and bioequivalence, failure to timely report the distribution of drugs that were out-of-specification and attempts to conceal violations of the FDA’s Good Manufacturing Practices.

Ranbaxy had further been questioned over the use of pharma ingredients from unapproved sources, mixing of approved ingredients with unapproved ones and having reduced quantity of the pharmaceutical ingredient in a drug approved by the FDA.

Such actions could lead to the medicine being “sub-potent, super-potent or adulterated,” the DoJ said.

At the heart of this controversy was Ranbaxy’s plant at Paonta Sahib, Himachal Pradesh, that was inspected by the FDA in 2006. Ranbaxy on its part maintains that all information required by the US authorities will be submitted.

But is it only about documentation and “semantics”, questions another Mumbai-based industry expert. The FDA definition of an adulterated drug varies from the local understanding, where adulterated means not containing the ingredient it claims to contain, i.e. a crocin containing chalk powder and no pharmaceutical ingredient, he explains.

But why would documentation related issues take three years to resolve, he questions, pointing out that something was amiss. Ranbaxy should have given all required documents when it was first asked for and not allowed matters to come to such a pass, he adds.

There are several interested quarters gunning for the generics industry, as the latter provide medicines that are chemically similar to innovative medicines, and at a much lower cost, explains a seasoned industry official.

The US accounts for over half of the $680-billion-plus global pharmaceutical market. And of this, the global generic drugs market is about $60 billion and the US accounts for over half of this market as well.

About 45 per cent of Dr Reddy’s Laboratories’ generic revenue comes from North America; Wockhardt sells 58 products in the US; Glenmark’s generic sales in the US grew last year by 155 per cent and Sun Pharma’s US sales grew 167 per cent last year – to name just a handful of Indian companies that sell in the US.

There are a host of smaller and mid-sized companies as well that sell to larger companies in the US.

And that explains why more than just Ranbaxy’s management are closely watching developments in the US.

[Anonymous]

And will someone please wake up the media? They are trained and paid to have inquiring minds, yet they obediently parrot whatever the company says instead of taking pause to question how ridiculous some of the company's claims are.

Read this story from The Star Ledger, New Jersey's largest newspaper. The Star Ledger follows the pharma industry very closely because of the concentration of this industry in that state.

http://www.nj.com/starledger/stories/index.ssf?/base/news-0/1216528513288450.xml&coll=1&thispage=1

[Anonymous]

Read this story from The Star Ledger, New Jersey's largest newspaper. The Star Ledger follows the pharma industry very closely because of the concentration of this industry in that state.

http://www.nj.com/starledger/stories/index.ssf?/base/news-0/1216528513288450.xml&coll=1&thispage=1

From the story above:

"Ranbaxy needs to think through the implications for the criminal case of providing the audits," Deborah Autor, director of Compliance for the FDA's Center for Drug Evaluation and Research and a former federal prosecutor, wrote in an August 2007 e-mail to Ranbaxy's lawyers.

For eleven whole months, the company did nothing. Lethal combnation of arrogance and ignorance. Remind me, how much did they spend on lawyers - both internal and external - who were advising them on this case?

[Anonymous]

It would appear that at each and every significant decision point in handling the response to the FDA criminal investigation the Ranbaxy brain trust, MMS, VK,and JD have made the wrong moves. It is hard to imaging how any group of people could have such poor judgment.

One thing these clowns have succeeded in doing is making the FDA investigation not their most serious problem. Now that this has come so clearly into the public eye and is about to enter the political circus their US business will be in a death spiral. Ranbaxy does not have a single significant product in the US that can't be obtained from suppliers whose product safety has not been questioned. It will be years, if ever, for the business to recover.

How much longer before the EMEA wakes up? Does anyone believe that Ranbaxy's fraudulent product development was limited to the US?

[Anonymous]

There is a lot of hand wringing going inside the company because one of the Congressmen who has questioned the FDA's lapses in curbing Ranbaxy imports and approvals (Stupak) has an extremely negative stance on Accutane/Isotretinoin. Ranbaxy's generic version of Accutane is the leader in that market, making it an easy and convenient target for Stupak to take aim at.

Stupak is going to come after them hard and Ranabxy doesn't have enough influence on the Hill to reduce and deflect the degree of scrutiny it is going to be subjected to.

[Anonymous]

It is hard to imaging how any group of people could have such poor judgment.

Malav is trying to turn this into a generic versus Big Pharma issue. Having sold Ranbaxy to a Big Pharma company himself, he doesn't really have any grounds to make that claim!

[Anonymous]

Typo in the above posting: Word should be spelled Ulterior

[Anonymous]

I have a hard time understanding how congress, the FDA or the DOJ will stop Ranbaxy's product sales based on allegations. Without evidence that these products occured, and as long as Ranbaxy's drugs meet specs in the US, there should be no issues. And if the FDA had evidence of these allegations, Ranbaxy would already be shut down.

If you think the DoJ gets involved in cases where it does not see a reasonable semblance of criminal activity, you're naïve.

The point is Ranbaxy's drugs were NOT meeting US specs....that's what triggered this in the first place. In addition to reports from its inspectors, the FDA was acting on tips from former and current employees and invested a lot of time, money and effort to investigate this very, very closely. What they found confirmed a pattern of deliberate fraud, deception and wrongdoing.

And in a tacit admission of guilt, Ranbaxy refused to part with documents the FDA and DoJ were seeking up until 30 minutes before the motion was to be filed (which is when they finally realized the true import of events that were unfolding).

Sit back and enjoy the ride. Hopefully you enjoy roller coasters.

[Anonymous]

If you think the DoJ gets involved in cases where it does not see a reasonable semblance of criminal activity, you're naïve.


Which is why the DOJ itself is under investigation for firing prosecutors who were not bringing bogus fraud investigations against democratic politicians for republican political gain. Explain that Sherlock.

[Anonymous]

I have a hard time understanding how congress, the FDA or the DOJ will stop Ranbaxy's product sales based on allegations. Without evidence that these products occured, and as long as Ranbaxy's drugs meet specs in the US, there should be no issues. And if the FDA had evidence of these allegations, Ranbaxy would already be shut down.

You seem to understand what is going on about as well as Ranbaxy management.

There has been a steady stream of news about substandard and in some cases dangerous products from outside the US, mainly China. People have died from tainted heparin, there have been several instances of tainted food products, and potentially dangerous toys, for example painted with lead based paint. People are pissed that the FDA and CPSC haven't done more.

There already has been enough news to know that Ranbaxy has sold, or at least attemped to get approval to sell, fraudulently developed products in the US. Why some people continue to ignore this remains a mystery to me.

At this point it won't be the FDA, DOJ, or Congress that stops the sale of Ranbaxy products. Once Congress holds hearings, Ranbaxy's fraud or attemped fraud will be on the national news and it probably will be magnified. Perception will then be more important than reality and will beome the reality,

People then will refuse to accept or buy Ranbaxy products and that is what will kill their business. There is no reason to buy products whose safety and effiicacy is questioned when all of Ranbaxy's significant products are available from numerous other generic suppliers who have not been accused of fraud.

[Anonymous]

Perception will then be more important than reality and will beome the reality. People then will refuse to accept or buy Ranbaxy products and that is what will kill their business.

There it is folks, this is what its all about. It doesn't matter what is true, only what you can get people to believe. It matters not if Ranbaxy is guilty, they are a bunch of scum bag Indians and they must be crooked. All it takes is a few unsubstantiated allegations, a willing media and some grandstanding Congressman and voila, you can destoy a multi-billion dollar company.

Have you ever stopped to think that the FDA, following the heparin scandal, would not want to be embarassed twice. With all the thousands of pages of data Ranbaxy has provided, multiple facility audits, depositions and everything else, if the FDA thought Ranbaxy was guilty of these allegations, they would not be sitting on their hands. I am surprised the posters on this board are willing to believe that Ranbaxy employees would, as a matter of business practice, falsify information and defraud the US government........yet, they refuse to believe that an employee of a competitor or a disgruntled ex-Ranbaxy employee would make bogus allegations to the FDA.

It is possible that the DOJ is chasing a phantom because of some joker's attempt to take down Ranbaxy.

I think this quote accurately sums up the current situation, "Nothing is as good as it seems, nothing is a bad as it seems. Somewhere in the middle, lies reality."

[Anonymous]

A few unsubstantiated allegations from disgruntled ex-employees or competitors do not lead to a 3 year federal investigation and a 3 year absence of approvals that is not challenged in court by the affected company. This continuing idea that Ranbaxy is some innocent company being persecuted by the FEDs is ludicrious and anyone who believes this is just swallowing Ranbaxy's BS.

Now that this matter has moved into the political arena Ranbaxy's problems may be magnified and maybe beyond what can be substantiated. Malav and his cronies have no one to blame but themselves. At any point in the last 5 to 10 years Malav and his cronies could have stopped the illegal activities. Once the investigation started they had many opportunities to manage it so that the damage was minimized. Their own stupidity and unsofistication got them to this point and the best they can come up with is excuses that convince only the most gullible.

[Anonymous]

At any point in the last 5 to 10 years Malav and his cronies could have stopped the illegal activities.

Malav's only been CEO for like 2 years dummy.

[Anonymous]

Malav's only been CEO for like 2 years dummy.

If there is a dummy it must be you. Malav became President and then CEO by ousting DSB which to any thinking person makes it clear he had the power all along.

And, if you are dumb enough to think that prior to that he was completely ignorant of what was going on and could not have stopped it if he had the necessary integrity and vision then you have no clue as to what has gone on in Ranbaxy.

Malav may try to sell the "I am innocent because I have only been CEO for 2 years" (actually 2 1/2) but only his puppets and syncophants will buy it.

[Anonymous]

The problem of data management in Ranbaxy dates back to 2002.
That was the time Rajiv Malik became Head of Product Development and
Regulatory.He actually moved out
stability study from QA to R&D under Chandrasekhar.So there was no checks
and balances on data integrity. In those days Ranbaxy used file record
number of ANDAs and people used to boast about this and hog all the lime light.The trio , Rajiv Malik, Chandrasekhar and Abha Pant used to rule and anybody objecting were sidelined or pushed out of company.Financially also they were rewarded handsomely.
When Dr Rashmi Barbhaiya joined Ranbaxy as Head of R&D, Rajeev Malik started getting questioned and ultimately had to resign. The other two crooks survived since Dr Barbhaiya himself resigned and moved out.
After Rajiv Malik moving out,Ranbaxy restored stability study under QA(probably realising damages done already).
The irony is ,the stability study department is now again assigned to Chandrasekhar and not that only,he is now Global QA head of Ranbaxy.
Abha Pant has moved up as Global Head of Regulatory.She was instrumental for filing false or doctored data of bio availability and stability.
One simply wonder why Malav is backing these crooks!!

[Anonymous]

Who are you???
An Ex head of QA of Ranbaxy or one of the present ones???

[Anonymous]

How does it matter? Are you disputing the facts?
I guess you are one of the crooks.

[Anonymous]

One simply wonder why Malav is backing these crooks!!

Oh, that's simple. In this company, if you are incompetent, crude and arrogant - you make the cut and are on the high speed elevator to the corner office. The coterie is like a bunch of rural folks that manage the affairs of the company on heresay. If you are one of them, not only are your worst mistakes pardoned, but you get rewarded handsomely too: it is visible all around - most of the VPs are past their prime, pedestrian in their capability, and they are still doled out golden handcuffs! I think golden handcuffs are being given to fool DS into believing that the company has real talented senior management that it could lose in the instability following this deal. Poor DS doesn't realise that bulk of these VPs wouldn't get a job in the next door diner if they went for 10% of their current compensation! This is true for most functions - technical, business or corporate.